Erin Harris

Erin Harris

Erin Harris is the editor-in-chief at Cell & Gene.

ARTICLES BY ERIN HARRIS

  • Philadelphia: The Cell And Gene Therapy Sector’s New Normal
    Philadelphia: The Cell And Gene Therapy Sector’s New Normal

    Being a Greater Philadelphia Area resident affords me the opportunity to meet and collaborate with scientists, doctors, researchers, and other highly skilled professionals knee-deep in the cell and gene therapy sector. From the University of Pennsylvania to CHOP to Spark Therapeutics to Tmunity and many, many more, Philadelphia not only continues to shine as the geographical standout for innovation and continuous forward movement for cell and gene therapies but also as the smart economical choice for SMEs in the field.

  • Adaptimmune’s VP QA CMC Talks Quality Management
    Adaptimmune’s VP QA CMC Talks Quality Management

    One conversation with Michael Blackton, VP QA CMC at Adaptimmune, proves why he is known for being a passionate, results-oriented leader focused on QA, analytical development, and more. Validate for yourself as Blackton answers my questions about process development and quality management. And, he provides a fresh outlook on recruiting senior-level executives.  

  • The Status of Regulatory Framework For Cell And Gene Therapies
    The Status of Regulatory Framework For Cell And Gene Therapies

    Jiwen Zhang, Executive Director, Regulatory Affairs at Tmunity Therapeutics Incorporated and Cell & Gene Editorial Advisory Board member explains the status of the cell and gene sector’s domestic and international regulatory framework. As President of the International Standards Coordinating Body (SCB), she also provides a synopsis of the most recent Stakeholder meeting.

  • ARM’s CEO Recaps 2018 Meeting On The Mesa
    ARM’s CEO Recaps 2018 Meeting On The Mesa

    Cell & Gene Meeting on the Mesa took place last month in La Jolla, CA, and it’s no surprise that ARM delivered meaningful data and addressed cutting-edge research to more than 1,200 attendees. I caught up with ARM’s CEO Janet Lambert after the Meeting to get her take on top highlights, the most informative panel discussions, as well as a look ahead to next year’s event. Here’s what she had to say.

  • Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals
    Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals

    In part two of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and ISCT’s Chief Commercialization Officer, he answers my questions about the Society’s near-term goals and objectives as well as his top areas of focus as CCO.

  • ISCT’s Miguel Forte On Academic-To-Industry Translation
    ISCT’s Miguel Forte On Academic-To-Industry Translation

    In part one of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and Chair of Commercialization Committee at ISCT, he answers my questions about academic-to-industry translation, the root cause of unproven therapies, how the industry is combatting them, and more.

  • CAR-T And The Voice Of The Patient
    CAR-T And The Voice Of The Patient

    Cell & Gene Editorial Advisory Board member answers questions about his message to pharma executives, researchers, scientists, and doctors, what the industry should consider when developing new payment structures, and more.

  • The FDA’s Dr. Peter Marks On The Current State Of Cell And Gene Therapies
    The FDA’s Dr. Peter Marks On The Current State Of Cell And Gene Therapies

    Peter Marks, MD, PhD, Director Center for Biologics Evaluation and Research at U.S. Food and Drug Administration answered some of my questions about the current state of the FDA’s regulations around cell and gene therapies, its stance on international harmonization required to make cell and gene therapies more streamlined, the reasons why it is critical for companies to begin working with the FDA early in the development process, and more. Read on for Dr. Marks' insightful responses.

  • A Sit Down With ARM’s CEO, Janet Lambert
    A Sit Down With ARM’s CEO, Janet Lambert

    Janet Lambert, joined the Alliance for Regenerative Medicine (ARM) as CEO just over a year ago. And what a year it’s been. Recently, I had the opportunity to talk to Lambert about her first year as CEO, what ARM is doing in cell and gene therapies from clinical and commercialization points of view, as well as its areas of short-term focus. Here’s what she had to say.